$1.00
5.26%
Nasdaq, Oct 01, 03:39 pm EDT. Closed.
ISIN
US10501E2019
Symbol
BCLI

Brainstorm Cell Therapeutics Inc. Stock price

$1.00
-0.17 14.35% 1M
+0.05 5.29% 6M
+0.45 80.83% YTD
+0.29 40.17% 1Y
-2.00 66.62% 3Y
-46.70 97.90% 5Y
-35.15 97.23% 10Y
+0.72 257.14% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
+0.05 5.26%
ISIN
US10501E2019
Symbol
BCLI
Industry

Is Brainstorm Cell Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$11.0m
Enterprise Value
$10.6m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-423.8%
Return on Equity
149.7%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
6.5%
Employees
23
Rev per Employee
$0.0

Brainstorm Cell Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Brainstorm Cell Therapeutics Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Brainstorm Cell Therapeutics Inc. forecast:

Hold
50%
Sell
50%

Financial data from Brainstorm Cell Therapeutics Inc.

Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.31 7.31
27% 27%
-
- Research and Development Expense 4.99 4.99
43% 43%
-
-12 -12
35% 35%
-
- Depreciation and Amortization 0.23 0.23
12% 12%
-
EBIT (Operating Income) EBIT -12 -12
34% 34%
-
Net Profit -11 -11
29% 29%
-

In millions USD.

Don't miss a Thing! We will send you all news about Brainstorm Cell Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Brainstorm Cell Therapeutics Inc. Stock News

Neutral
PRNewsWire
●
about one month ago
Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.
Neutral
PRNewsWire
●
about 2 months ago
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOw...
Neutral
PRNewsWire
●
2 months ago
Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerat...
More Brainstorm Cell Therapeutics Inc. News

Company Profile

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Head office United States
CEO Mr. Lebovits
Employees 23
Founded 2000
Website brainstorm-cell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today